Register
Patient wearing CGM sensor on arm with glucose data on smartphone

TECHNOLOGY

15 Apr 2026

Beyond Insulin: CGM Earns Its Place in Type 2 Care

Real-world data from ATTD 2026 shows CGM tech from Dexcom and Abbott delivers measurable gains across the full type 2 diabetes spectrum

Hims and Hers branded compounded semaglutide vials side by side

PARTNERSHIPS

14 Apr 2026

The Weight-Loss War Just Turned Into a Partnership

Novo Nordisk and Hims & Hers settle a patent fight and strike a deal to sell branded GLP-1 drugs via telehealth

Person self-administering insulin pen injection with CGM sensor on arm

INSIGHTS

13 Apr 2026

The GLP-1 Revolution Reaches Type 1 Diabetes

A Johns Hopkins study finds GLP-1 receptor agonists cut cardiovascular and kidney risk in type 1 diabetes patients, drawing on 175,000 US ...

Pfizer logo on glass office building exterior

RESEARCH

10 Apr 2026

The Monthly Weight-Loss Shot That Hasn't Peaked Yet

Pfizer's monthly GLP-1 shot hit its Phase 2b weight loss target at 28 weeks, with no plateau in sight

Novo Nordisk company sign with brand logo

REGULATORY

9 Apr 2026

One Injection, One Week: Novo Nordisk Clears a New Bar

Novo Nordisk's Awiqli cuts basal insulin injections from seven per week to one after FDA approval on March 26, 2026

Close-up of Foundayo weight-loss medication tablet

INNOVATION

8 Apr 2026

A Weight-Loss Pill Without the Strings Attached

Eli Lilly's once-daily GLP-1 pill Foundayo wins FDA approval, offering needle-free obesity care from $25 a month

topics on the agenda

AI-DISCOVERED PEPTIDES: A NON-PHARMACEUTICAL BREAKTHROUGH FOR WEIGHT MANAGEMENT

DAY 1: undefined

09:40 - 10:05

GLOBAL PREVENTION OF DIABETES

DAY 1: undefined

10:10 - 10:35

PANEL DISCUSSION ON THE SILENT EPIDEMIC OF METABOLIC SYNDROME

DAY 1: undefined

11:00 - 11:30

View more topics

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.